

Review

Open Access

Regulation of cellular proliferation, differentiation and cell death by activated Raf

Gerald Thiel*, Myriam Ekici and Oliver G Rössler

Address: Department of Medical Biochemistry and Molecular Biology, University of Saarland Medical Center, Homburg, Germany

Email: Gerald Thiel* - gerald.thiel@uks.eu; Myriam Ekici - myriamekici@web.de; Oliver G Rössler - bcoroe@uniklinik-saarland.de

* Corresponding author

Published: 21 April 2009

Received: 20 February 2009

Cell Communication and Signaling 2009, **7**:8 doi:10.1186/1478-811X-7-8

Accepted: 21 April 2009

This article is available from: <http://www.biosignaling.com/content/7/1/8>

© 2009 Thiel et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The protein kinases Raf-1, A-Raf and B-Raf connect receptor stimulation with intracellular signaling pathways and function as a central intermediate in many signaling pathways. Gain-of-function experiments shed light on the pleiotropic biological activities of these enzymes. Expression experiments involving constitutively active Raf revealed the essential functions of Raf in controlling proliferation, differentiation and cell death in a cell-type specific manner.

Introduction

All three Raf isoenzymes are cytosolic serine/threonine protein kinases that exhibit a high degree of sequence similarity. The enzymes contain three domains termed CR1, CR2 and CR3. The N-terminal CR1 contains a Ras-binding subdomain and a cysteine-rich subdomain, both required to bind to activated Ras (Ras-GTP) at the cell membrane. CR2 is rich in serine and threonine residues and negatively regulates the biological activity of the catalytic domain. CR3 contains the catalytic protein kinase domain (figure 1).

Raf connects cellular stimulation with intracellular signaling pathways. Raf translocates to the plasma membrane as a result of receptor tyrosine kinase stimulation that leads to a subsequent activation of Ras. Following activation, Raf phosphorylates and activates mitogen-activated protein kinase (MAP) kinase (MEK) which in turn phosphorylates and activates the MAP kinases extracellular signal-regulated protein kinases ERK1 and ERK2 [1]. Raf functions therefore as a vital link between activated Ras and ERK. The activated protein kinases ERK1/2 are able to translocate into the nucleus and change the gene expres-

sion pattern via phosphorylation of gene regulatory proteins. Thus, activation of Raf is essential for activating the Raf/MEK/ERK signaling pathway and many functions attributed to Raf activation are executed by the subsequent activation of MEK and ERK. A microarray analysis confirmed that the transcriptional response to Raf activation almost completely depends on MEK activation [2]. In line with this, MEK is the only generally acknowledged substrate for Raf [1,3].

Lessons from Raf-deficient mice

Gene ablation experiments involving the genes encoding the Raf isoforms Raf-1, A-Raf, and B-Raf revealed divergent phenotypes, indicating that Raf isoforms are not always able to compensate for each other. In particular, distinct essential functions are served by Raf-1 and B-Raf in embryonic development [4]. Nevertheless, a functional redundancy among the Raf family proteins exists and only phenotypes requiring the activity of a distinct Raf isoform are found. Inactivation of the Raf-1 and B-Raf-encoding genes revealed that Raf-1 and B-Raf play essential anti-apoptotic roles [5,6]. B-Raf is necessary for survival of embryonic motoneurons and sensory neurons [7]. Several




Figure 1
Modular structure of Raf. The Raf isoforms Raf-1, A-Raf and B-Raf share three conserved domains termed CR1, CR2 and CR3. CR1 contains a Ras-binding subdomain and a cysteine-rich subdomain, both required to bind to activated Ras (Ras-GTP) at the cell membrane. CR2 is rich in serine and threonine residues and negatively regulates the biological activity of the catalytic domain. This domain binds also regulatory 14-3-3 proteins. CR3 encompasses the protein kinase domain.

review articles have been published that discuss these mouse models in detail [4,8-10]

Gain-of-function mutants of Raf

Two strategies have been used to express constitutively active Raf. The translocation of Raf to the plasma membrane via binding to Ras-GTP is the key event in Raf activation [1]. Thus, a method to express a constitutively active Raf-1 relies in the tethering of Raf to the plasma membrane. This Raf-1 mutant termed Raf-CAAX carries at the C-terminus an isoprenylation sequence derived from K-Ras [11,12]. The artificial targeting of Raf-1 to the plasma membrane leads to an activation of the enzyme in a Ras-independent manner and shows 30-fold higher kinase activity in growth-factor-deprived cells.

Alternatively, expression of the catalytic domain of either Raf-1, B-Raf, or A-Raf as a fusion protein with the hormone binding domain of the estrogen receptor [ER] generates a hormone-regulated constitutively active Raf. The Δ Raf:ER fusion protein remains in an inactive state in the absence of hormone, but is rapidly activated by the addition of hormone [13]. Figures 2A and 2B outline the strategy of using steroid-binding domains for regulating the function of Raf *in cis* [14]. In the absence of hormone, a heat-shock protein such as Hsp90 binds to the estrogen receptor domain and inhibit the catalytic function of the Raf-estrogen receptor fusion protein by steric hindrance, thus keeping the protein in an inactive state. Treatment

with estrogen triggers the dissociation of the heat-shock proteins, leading to a reversal of repression. As a result, Raf activity can be hormonally controlled. The use of the estrogen receptor mutant ER^{Tamoxifen Mutant} allows the use of the synthetic ligand, 4-hydroxytamoxifen (4OHT) for induction. The encoded hormone binding domain of the estrogen receptor contains a glycine residue at position 525, instead of an arginine. As a result, the receptor is largely insensitive to 17 β -estradiol, but is readily activated by 4OHT [15]. The activation of the ERK signaling pathway can be visualized by Western blot analysis using antibodies that specifically recognize the phosphorylated forms of ERK1 and ERK2 (figure 2C). In this review, we will summarize some of the findings obtained with cells expressing Raf-estrogen receptor fusion proteins, which we consider the most important ones.

Role of Raf in the regulation of proliferation

The fact that Raf is activated following stimulation of the cells with mitogens (i.e. EGF, PDGF, IGF) indicates that these enzymes are involved in the regulation of cell growth and proliferation. Accordingly, expression of the hormone-regulated form of Raf-1, Δ Raf-1:ER, induced cell proliferation in NIH 3T3 fibroblasts that was accompanied by an upregulation of cyclin D1 and a repression of p27^{KIP}, a cyclin-dependent protein kinase inhibitor [16]. Expression of conditionally active forms of A-Raf and B-Raf in NIH 3T3 cells revealed differences between the individual Raf isoforms. While the activation of both Δ A-Raf:ER and Δ B-Raf:ER induced the activation of MEK and ERK protein kinases, Δ B-Raf:ER activated MEK with the highest efficiency [17]. A microarray analysis performed with human epithelial cells underlined the importance of MEK activation by Raf [2]. Moreover, the fact that activation of Δ Raf:ER strongly induced the expression of growth factors of the EGF growth factor family suggests the existence of an autocrine loop through the activation of the EGF receptor: Activation of Δ Raf:ER triggers the stimulation of the EGF receptor. As a result, the Raf-MEK-ERK signaling pathway is activated, leading to further synthesis of EGF growth factors [2,18].

In keratinocytes, activation of the EGF receptor triggers proliferation of the cells and involves the ERK signaling pathway (figure 3A) [19]. The importance of the ERK signaling pathway for growth of human keratinocytes was further demonstrated with HaCaT keratinocytes expressing Δ A-Raf:ER. Proliferation of the cells was induced with 4OHT and completely inhibited by pretreatment with the MAP kinase kinase inhibitor PD98059 (figure 3B), indicating that the mitogenic activity of Δ A-Raf:ER is mediated by the activation of ERK. A comparison between the kinetics of ERK phosphorylation and activation by EGF or 4OHT revealed major differences in the duration of ERK activation (figure 3C). While EGF induced a strong phos-




Figure 2

Figure 2
Design and biological activity of a conditionally active forms of Raf. (A) Strategy: A heterologous protein is expressed as a fusion protein with the ligand-binding domain of the estrogen receptor. The fusion protein, that is constitutively expressed, remains in an inactive state, due to the binding of chaperons of the Hsp90 family. The repression is reversed by adding hormone. (B) Modular structure of Raf and Δ Raf:ER, a conditionally active form of Raf-1. (C) Biologically active Δ Raf-1:ER triggers phosphorylation and activation of ERK2. HT22 cells, murine cells of hippocampal origin, and HT22- Δ Raf-1:ER cells were treated with 4OHT (+) or left untreated (-). Whole cell extracts were prepared 15 min after stimulation and subjected to Western blot analysis. The blots were incubated with a rabbit antibody directed against the phosphorylated form of ERK1/2.

phorylation of ERK within 1 hour after stimulation, phosphorylated ERK was barely detected in Δ A-Raf:ER expressing keratinocytes that had been incubated for 1 hour with 4OHT. Phosphorylated ERK was, however, detected in these cells 4 and 8 hours after induction of Δ A-Raf:ER. These results indicate that the kinetics of ERK activation (transient versus sustained) are of minor importance for the induction of the mitogenic program of keratinocytes by A-Raf. This observation is in contrast to the role of ERK in neuronal survival where a sustained activation of ERK is required for neuroprotection (see below).

In a human breast epithelial cell line, activation of Δ Raf:ER triggered the expression of genes encoding regulators of cell proliferation, including cyclin D1, and induced a transient increase in S phase cells. However, Raf activation did not induce growth factor-independent proliferation [18], in contrast to the situation encountered with Δ A-Raf:ER expressing keratinocytes. These data indicate that cell-type specific variations are important for the biological outcome of Raf activation.

Although the activation of a conditional form of Raf can promote DNA synthesis and cellular proliferation, other reports show that it can also provoke cell cycle arrest. Expression of Δ Raf-1:ER in small lung cancer cells induced a growth inhibitory pathway that is accompanied by the induction of the cyclin-dependent protein kinase inhibitor p27^{KIP} and a decrease in cdc2 protein kinase activity [20]. In prostate cancer cells, activation of Δ Raf-1:ER induced expression of the cyclin-dependent protein kinase inhibitor p21^{KIP} and an accumulation of the cells in G1, thus leading to growth suppression [21]. Likewise, Δ Raf-1:ER and Δ B-Raf:ER elicited a G1 arrest in NIH 3T3 cells that was accompanied by an upregulation of the cyclin-dependent protein kinase inhibitor p21^{KIP}. In contrast,

activation of ΔA -Raf:ER promoted the entry of quiescent NIH 3T3 cells into the S-phase of the cell cycle. A catalytically potentiated form of ΔA -Raf:ER, however, induced cell cycle arrest and enhanced p21^{KIP} expression, similarly to ΔB -Raf:ER or Δ Raf-1:ER [22]. These data suggest that the catalytical activity and the duration of the signaling of Raf might determine the role of these enzymes in the progression of the cell cycle. In addition, cell type-specific differences are essential for Raf induction and impairment of the growth capacity of the cells.

Anti-apoptotic role of Raf

Raf-1-deficient embryos are growth retarded and apoptotic cells are found in different tissues [6,7]. Raf-1-deficient fibroblasts are hypersensitive to apoptotic stimuli such as serum withdrawal or Fas/Fas ligand interaction. Thus, it was concluded that the major function of Raf-1 is to counteract apoptosis [7]. Also B-Raf-deficient embryos die because of vascular defects due to apoptotic death of differentiated endothelial cells [23].

The activation of the MEK/ERK signaling pathway by Raf has been correlated with inhibition of programmed cell death. The ERK signaling pathway has been described to play an important role as a main antagonist of various apoptosis-inducing challenges [[24,25]; reviewed in ref [26]]. Activation of the ERK signaling pathway suppresses the proapoptotic activity of stress-activated JNK/p38 protein kinases in PC12 pheochromocytoma cells, thus protecting the cells from NGF withdrawal-induced cell death [27]. In line with this, BDNF-elicited ERK activation protects cortical neurons against a challenge with the topoisomerase I inhibitor camptothecin [28]. In addition, it has been shown that activation of the ERK signaling pathway via treatment of the cells with either EGF or 12-O-tetradecanoylphorbol-13-acetate may lead to an inactivation of caspase-9 due to a direct phosphorylation of Thr125 of caspase-9 by ERK. This phosphorylation blocks caspase-9 processing and the subsequent activation of caspase-3 [29].

The survival of cells requires the presence of survival factors, and the lack of this trophic support is one of the best-studied signals for induction of cell death. In Rat-1 fibroblasts, overexpression of B-Raf protected the cells from apoptosis, induced by growth factor withdrawal. Treatment with the MEK inhibitor PD98059 blocked the anti-apoptotic activity of B-Raf, indicating that the activation of the Raf-MEK-ERK signaling pathway is necessary for the anti-apoptotic role of B-Raf in Rat-1 fibroblasts [30].

Experiments using HT22 immortalized neurons derived from the hippocampal region of the CNS showed that stimulation with BDNF rescues the cells from serum withdrawal-induced cell death when the BDNF receptor TrkB




Figure 3

Figure 3**Activation of a conditionally active form of A-Raf(Δ A-Raf:ER) induces proliferation of human HaCaT keratinocytes via activation of the ERK signaling pathway.**

(A, B) Stimulation of HaCaT- Δ A-Raf:ER cells with either EGF (1 ng/ml) (A) or 4OHT (25 nM) (B) leads to an upregulation of DNA synthesis, as measured by the incorporation of the pyrimidine analogue 5-bromo-2'-deoxyuridine (BrdU) instead of thymidine into the DNA of proliferating cells. The incorporated BrdU was detected by immunoassay. Mitogenic signaling induced by EGF or 4OHT was completely abrogated by the MAP kinase kinase inhibitor PD98059. (C) Kinetics of ERK activation in EGF and 4OHT treated HaCaT- Δ A-Raf:ER cells. Whole cell extracts were prepared from cells at different time points and subjected to Western blot analysis. The blots were incubated with an affinity purified rabbit antibody directed against the phosphorylated (active) form of ERK2 (reproduced from [19] with copyright permission from the American Physiological Society).

is expressed. An analysis of intracellular signaling cascades revealed that stimulation of the TrkB receptor with BDNF leads to an activation of both the ERK and the PI3 kinase pathways. A pharmacological approach showed that the major neuronal survival-promoting signaling pathway includes an activation of PI3 kinase and AKT [31]. These and other observations [28] indicate that the signaling cascade BDNF \rightarrow TrkB stimulation \rightarrow PI3 kinase activation \rightarrow activation of AKT \rightarrow cell survival is of general importance and is not limited to a particular neuronal population or neuronal cell line. In contrast, the neuroprotective activity of BDNF is independent of the ERK signaling pathway since PD98059 did not impair the BDNF-mediated protection of neurons against serum withdrawal-induced programmed cell death. To clarify the role of ERK for neuroprotection, HT22 cells were analyzed that expressed a Δ Raf-1:ER fusion protein and allowed the selective activation of the ERK signaling pathway (figure 2C). Activation of the catalytic function of Raf-1 by 4OHT rescued HT22 cells from serum withdrawal-induced cell death, as depicted in figure 4A. The neuroprotective role of Δ Raf-1:ER was confirmed by phase contrast microscopy (figure 4B). Inhibition of Δ Raf-1-induced MEK activation by PD98059 blocked the cytoprotective activity of Δ Raf-1:ER [31], indicating that the activation of ERK via MEK is the underlying cause for neuroprotection mediated by the activation of the Δ Raf-1-ER fusion protein. These results were a puzzle to be solved: BDNF-mediated neuroprotection against serum withdrawal-mediated cell death was independent of ERK; in contrast, the Raf-1-estrogen receptor fusion protein protected the cells solely via activation of the ERK signaling pathway. To find clues to the solution of the puzzle, the kinetics of ERK activation in HT22 cells

have been investigated (figure 4C). Stimulation of TrkB expressing HT22 cells with BDNF triggered a robust, but transient activation of ERK that was not sufficient to confer protection against the loss of trophic support. In contrast, expression of a conditionally activatable Raf-1 that induced a sustained ERK phosphorylation lasting for hours, rescued neuronal HT22 cells from serum deprivation-induced cell death. The phosphorylation state of the ERK substrate Elk-1 mirrored the kinetic profile of ERK activation, i.e. transient or sustained activation of ERK is translated in the nucleus into a transient or sustained activation of Elk-1 (figure 4C). We then asked the question how long ERK has to be activated in order to protect HT22 cells from serum deprivation-induced apoptosis. Addition of PD98059 at different time points following treatment of the cells with 4OHT revealed that a prolonged activation of ERK, lasting for hours, is necessary for neuroprotection [31] (figure 4D). These results shed light on the fact that the kinetics of ERK activation (transient versus sustained) are of major importance for the neuroprotective activity. Thus, activation of PI3 kinase by BDNF in neuronal cells represents the dominant survival pathway, whereas the ERK signaling pathway plays no or only a marginal role. However, a sustained activation of ERK, lasting for several hours, protects neurons from growth factor deprivation-induced cell death, indicating that the duration of ERK activation is of major importance for its neuroprotective biological function. Thus, stimulation of the cells with neurotrophins of elevated concentrations, or stimulation with several ligands, i.e. BDNF and EGF, may trigger a sustained activation of ERK.

The activation of an estrogen-inducible activated Raf-1 mutant Δ Raf-1:ER also prevented apoptosis induced by loss of matrix contact (anoikis), cytoskeletal integrity and serum removal in lung fibroblasts [32]. In these cells it has been shown that activation of Δ Raf-1:ER prevented the upregulation of Bim, a proapoptotic BH3-only protein of the Bcl-2 family, in serum-starved cells. This rescue relies on the activation of the ERK pathway and was independent of the JNK \rightarrow c-Jun and PI3 kinase \rightarrow PDK \rightarrow AKT pathway [33]. In human breast epithelial cells, the expression of genes encoding growth factors of the EGF family as a result of Δ Raf-1:ER activation protected the cells from detachment-induced apoptosis [18]. Activation of Δ Raf-1:ER also blocked programmed cell death induced by TGF β in MLCK epithelial cells [34]. However, activation of Δ Raf-1:ER did not provide protection against oxidative glutamate toxicity in HT22 hippocampal cells [35]. These data indicate that the anti-apoptotic function of Raf is restricted to particular apoptotic signaling pathways.

In addition to the well-established target MEK, Raf may use other effectors to inhibit programmed cell death. It has been shown that Raf-1 promotes cell survival in a




Figure 4 (see legend on next page)

Figure 4 (see previous page)

A conditionally active form of Raf-1 (Δ Raf-1:ER) protects HT22 neuronal cells against serum deprivation-induced cell death via activation of ERK. (A, B) Activation of Raf-1 provides protection against serum deprivation-induced apoptosis. HT22- Δ Raf-1:ER cells were serum-starved in the presence or absence of 4OHT (200 nM) for twenty-four hours. The reduction of colorless 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide by mitochondrial NAD(P)H-dependent dehydrogenases to formazan dye crystals was used as an indicator for cell survival (MTT assay). (A); , values statistically significantly different ($p < 0.005$) from those of cells incubated in the absence of serum and PD98059, but in the presence of 4OHT. (B) HT22 Δ Raf-1:ER cells or HT22pac cells were serum-starved in the presence or absence of 4OHT for twenty-four hours. The cytotoxic effect of serum withdrawal was determined by phase contrast microscopy. The neuroprotection was abrogated by incubation with the MEK inhibitor PD98059, indicating that the ERK signaling pathway is essential for Δ Raf-1:ER mediated neuroprotection. (C) Kinetics of ERK2 and Elk-1 phosphorylation after stimulation with BDNF or 4OHT. BDNF stimulation triggers a rapid, but transient activation of ERK in TrkB receptor expressing HT22 cells (HT22-TrkB.TK cells, upper panel), whereas activation of the Δ Raf-1:ER fusion protein leads to a sustained activation of ERK, lasting for hours (HT22- Δ Raf-1:ER cells, lower panel). The kinetics of ERK phosphorylation and activation correlate very well with phosphorylation and activity of the ternary complex factor Elk-1, a nuclear substrate of ERK that functions as a key regulator of serum response element-driven gene transcription. (D) Prolonged activation of ERK is essential for neuroprotection. HT22 cells expressing Δ Raf-1:ER were serum-starved and incubated with 4OHT for twenty-four hours. PD98059 was added simultaneously ($t = 0$), or eight ($t = 8$) or sixteen hours ($t = 16$) after stimulation of the cells with 4OHT. Cells were analyzed twenty-four hours after stimulation by either the MTT assay (left) or by phase contrast microscopy (right) (reproduced from [31] with copyright permission from Blackwell Publishing, Oxford).

MEK/ERK-independent manner via antagonizing apoptosis signal-regulating kinase-1 (ASK-1) [36]. Raf-1 is also targeted to the mitochondria by Bcl-2 that leads to cell survival without ERK activation, probably by phosphorylating substrates other than MEK, such as Bcl-2 family members [37,38].

Role of Raf in cellular differentiation

Raf activation has been discussed primarily as an integral part of the ERK signaling pathway controlling cellular growth. The impact of Raf in the control of cellular differentiation has only been put in the limelight in recent years. The lethal phenotypes observed in either Raf-1-, A-Raf- or B-Raf-deficient mice sheds light on the essential role of Raf during development. Nullizygous B-Raf^{-/-} embryos, for example, die by embryonic day 12.5 showing defects in vascular endothelial cell differentiation [23]. In cell culture models, B-Raf controls myelopoiesis at multiple stages. In particular, B-Raf deficient ES cells have a quantitative defect in myeloid progenitor cell formation [39]. B-Raf is also crucial for T-cell development, in particular for the transition to CD4⁺ and CD8⁺ single-positive cells [40]. In immortalized cells from rat hippocampus neurons, activation of Δ Raf-1:ER was shown to induce neuronal differentiation [41]. In neural stem cells, supplementation of the medium with EGF and bFGF is necessary to inhibit differentiation. Removal of the mitogens stops the cell cycle and induces differentiation [42]. Figure 5 shows that expression of the astrocytic marker GFAP is upregulated in differentiated HNSC.100 neural stem cells. This upregulation of GFAP expression was prevented in Δ Raf-1:ER-expressing neural stem cells that were stimulated by 4OHT in the absence of EGF and

bFGF in the medium [43], indicating that enhanced Raf-1 activity blocked the differentiation of the cells. Together, these data show that Raf influences developmental processes, although the exact molecular mechanisms have to be determined in each cell type.

Conclusion

Results obtained with constitutively active Raf mutants has been questioned, since the lack of the regulatory domains in the Raf mutants may compromise the substrate specificity and the dynamic regulation of activity [9]. Nevertheless, the many data obtained using these mutants have improved our knowledge of the functions of Raf in growth control, apoptosis and differentiation.

Abbreviations

ER: estrogen receptor; ERK: extracellular signal-regulated protein kinase; 4OHT: 4-hydroxytamoxifen

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

GT drafted and wrote the manuscript. ME and OR have critically revised the manuscript and prepared the figures. All authors read and approved the final manuscript.

Acknowledgements

We thank Martin McMahon, UCSF, for providing Δ Raf:ER constructs and Libby Guethlein for critical reading of the manuscript. The research of the laboratory concerning intracellular signaling cascades underlying neuronal cell death and survival is supported by the Deutsche Forschungsgemeinschaft (grant SFB 530, C14).




Figure 5

Figure 5

Activation of ΔRaf-1:ER blocks differentiation along the astrocytic lineage in human neural stem cells. (A) HNSC.100 neural stem cells expressing ΔRaf-1:ER were incubated with or without EGF, bFGF and 4OHT, as indicated. RNA was isolated and analyzed by RT-PCR. (B) Quantification and statistical analysis of the data shown in (A) (GFAP, glial fibrillary acidic protein; GAPDH, glyceraldehyde-3-phosphate-Dehydrogenase; IOD = Integrated optical density) (reproduced from [43], copyright by the American Society for Biochemistry and Molecular Biology).

References

- Wellbock C, Karasarides M, Marais R: **The Raf proteins take centre stage.** *Nat Rev Mol Cell Biol.* 2004, **5**(11):875-885.
- Schulze A, Nicke B, Warne PH, Tomlinson S, Downward J: **The transcriptional response to Raf activation is almost completely dependent on mitogen-activated protein kinase activity and shows a major autocrine component.** *Mol Biol Cell* 2004, **15**:3450-3463.
- O'Neill E, Kolch W: **Conferring specificity on the ubiquitous Raf/MEK signalling pathway.** *Br J Cancer* 2004, **90**:283-288.
- Baccarini M: **Second nature: Biological functions of the Raf-1 "kinase".** *FEBS Lett* 2005, **579**:3271-3277.
- Hülser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S, Sun XM, Brown J, Marais R, Pritchard C: **MEK kinase activity is not necessary for Raf-1 function.** *EMBO J* 2001, **20**:1940-1951.
- Mikula M, Schreiber M, Husak Z, Kucerova L, Rütth J, Wieser R, Zatloukal K, Beug H, Wagner EF, Baccarini M: **Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene.** *EMBO J* 2001, **20**:1952-1962.
- Wiese S, Pei G, Karch C, Troppmair J, Holtmann B, Rapp UR, Sendtner M: **Specific function of B-Raf in mediating survival of embryonic motoneurons and sensory neurons.** *Nat Neurosci* 2001, **4**:137-142.
- Hagemann C, Rapp UR: **Isotype-specific functions of Raf kinases.** *Exp Cell Res* 1999, **253**:34-46.
- Hindley A, Kolch W: **Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases.** *J Cell Sci* 2002, **115**:1575-1581.
- Galabova-Kovacs G, Kolbus A, Matzen D, Meissl K, Piazzolla D, Rubiolo C, Steinitz K, Baccarini M: **ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts.** *Cell Cycle* 2006, **5**:1514-1518.
- Leevers SJ, Paterson HF, Marshall CJ: **Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane.** *Nature* 1994, **369**:411-414.
- Stokoe D, Macdonald SG, Cadwallader K, Symons M, Hancock JF: **Activation of Raf as a result of recruitment to the plasma membrane.** *Science* 1994, **264**:1463-1467.
- McMahon M: **Steroid receptor fusion proteins for conditional activation of Raf-MEK-ERK signaling pathway.** *Meth Enzymol* 2001, **332**:401-417.
- Picard D: **Steroid-binding domains for regulating the function of heterologous proteins in cis.** *Trends Cell Biol* 1993, **3**:278-280.
- Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI: **A modified estrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins.** *Nucl Acids Res* 1995, **23**:1686-1690.
- Kerkhoff E, Rapp UR: **Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1.** *Mol Cell Biol* 1997, **17**:2576-2586.
- Pritchard CA, Samuels ML, Bosch E, McMahon M: **Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells.** *Mol Cell Biol* 1995, **15**:6430-6442.
- Schulze A, Lehmann K, Jefferies HB, McMahon M, Downward J: **Analysis of the transcriptional program induced by Raf in epithelial cells.** *Genes Dev* 2001, **15**:981-994.

19. Rössler OG, Thiel G: **Brain-derived neurotrophic factor-, epidermal growth factor-, or A-Raf-induced growth of HaCaT keratinocytes requires extracellular signal-regulated kinase.** *Am J Physiol Cell Physiol* 2004, **286**:C1118-C1129.
20. Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, Harter ML, Dillehay LE, Claudio PP, Giordano A, Nelkin BD, Mabry M: **Activated Raf-1 causes growth arrest in human small cell lung cancer cells.** *J Clin Invest* 1998, **101**:153-159.
21. Ravi BK, McMahon M, Yangang Z, Williams JR, Dillehay LE, Nelkin BD, Mabry M: **Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells.** *J Cell Biochem* 1999, **72**:458-469.
22. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M: **Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21^{Cip1}.** *Mol Biol Cell* 1997, **17**:5598-5611.
23. Wojnowski L, Zimmer AM, Beck TW, Hahn H, Bernal R, Rapp UR, Zimmer A: **Endothelial apoptosis in Braf-deficient mice.** *Nat Genet* 1997, **16**:293-297.
24. Holmström TH, Chow SC, Elo I, Coffey ET, Orrenius S, Sistonen L, Eriksson JE: **Suppression of Fas/APO-1-mediated apoptosis by mitogen-activated kinase signaling.** *J Immunol* 1998, **160**:2626-2636.
25. Tran SEF, Holmström TH, Ahonen M, Kähäri V-M, Eriksson JE: **MAP/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors.** *J Biol Chem* 2001, **276**:16484-16490.
26. Ballif BA, Blenis J: **Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals.** *Cell Growth Differ* 2001, **12**:397-408.
27. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: **Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.** *Science* 1995, **270**:1326-1331.
28. Hetman M, Kanning K, Cavanaugh JE, Xia Z: **Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase.** *J Biol Chem* 1999, **274**:22569-22580.
29. Allan LA, Morrice N, Brady S, Magee G, Pathak S, Clarke PR: **Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK.** *Nat Cell Biol* 2003, **5**:647-654.
30. Erhardt P, Schremser EJ, Cooper GM: **B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway.** *Mol Cell Biol* 1999, **19**:5308-5315.
31. Rössler OG, Giehl KM, Thiel G: **Neuroprotection of immortalized hippocampal neurons by brain-derived neurotrophic factor and Raf-1 protein kinase: Role of extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase.** *J Neurochem* 2004, **88**:1240-1252.
32. Le Gall M, Chambard JC, Breitmayer JP, Grall D, Pouyssegur J, Van Obberghen-Schilling E: **The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal.** *Mol Biol Cell* 2000, **11**:1103-1112.
33. Weston CR, Balmanno K, Chalmers C, Hadfield K, Molton SA, Ley R, Wagner EF, Cook SJ: **Activation of ERK1/2 by ΔRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways.** *Oncogene* 2003, **22**:1281-1293.
34. Lehmann K, Janda E, Pierreux CE, Rytömaa M, Schulze A, McMahon M, Hill CS, Beug H, Downward J: **Raf induces TGFβ production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells.** *Genes Dev* 2000, **14**:2610-2622.
35. Rössler OG, Bauer I, Chung HY, Thiel G: **Glutamate-induced cell death of immortalized murine hippocampal neurons: neuroprotective activity of heme oxygenase-1, heat shock protein 70, and sodium selenite.** *Neurosci Lett* 2004, **362**:253-257.
36. Chen J, Fujii K, Zhang L, Roberts T, Fu H: **Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism.** *Proc Natl Acad Sci USA* 2001, **98**:7783-7788.
37. Wang HG, Rapp UR, Reed JC: **Bcl-2 targets the protein kinase Raf-1 to mitochondria.** *Cell* 1996, **87**:629-638.
38. Zhong J, Troppmair J, Rapp UR: **Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria.** *Oncogene* 2001, **20**:4807-4816.
39. Kamata T, Kang J, Lee TH, Wojnowski L, Pritchard CA, Leavitt AD: **A critical function for B-Raf at multiple stages of myelopoiesis.** *Blood* 2005, **106**:833-840.
40. Tsukamoto H, Irie A, Senju S, Hatzopoulos AK, Wojnowski L, Nishimura Y: **B-Raf-mediated signaling pathway regulates T cell development.** *Eur J Immunol* 2008, **38**:518-527.
41. Kuo W-L, Abe M, Rhee J, Eves EM, McCarthy SA, Yan M, Templeton DJ, McMahon M, Rosner MR: **Raf, but not MEK or ERK, is sufficient for differentiation of hippocampal neuronal cells.** *Mol Cell Biol* 1996, **16**:1458-1470.
42. Villa A, Snyder EY, Vescovi A, Martínez-Serrano A: **Establishment and properties of a growth factor-dependent, perpetual neural stem cell line from the human CNS.** *Exp Neurol* 2000, **161**:67-84.
43. Ekici M, Hohl M, Schuit F, Martínez-Serrano A, Thiel G: **Transcription of genes encoding synaptic vesicle proteins in human neural stem cells: chromatin accessibility, histone methylation pattern, and the essential role of REST.** *J Biol Chem* 2008, **283**:9257-9268.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

